ArticleScientific reports2026
Hesperetin alleviates cerebral ischemia-reperfusion injury by suppressing neuronal ferroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hesperetin (HSP), a natural flavonoid, demonstrates significant therapeutic effects on cardiovascular and cerebrovascular diseases and displays a strong application potential in the aspects of anti-inflammation and anti-oxidation. Cerebral ischemia-reperfusion is accompanied by the generation of inflammatory storms and the accumulation of reactive oxygen species (ROS), ultimately resulting in neuronal damage. While Hesperetin has been widely studied in the treatment of cardiovascular diseases, its potential for treating cerebral ischemia-reperfusion injury remains underexplored. This study aimed to discuss the potential protective mechanism of HSP on cerebral ischemia-reperfusion injury (CIRI). Ferroptosis, a form of cell death driven by iron-dependent phospholipid peroxidation is associated with neuronal damage during cerebral ischemia and subsequent reperfusion injury. Our findings indicate that HSP can confer neuronal protection after CIRI by inhibiting neuronal ferroptosis. Specifically, HSP could significantly up-regulate glutathione (GSH) levels, and up-regulate glutathione peroxidase 4(GPX4) after CIRI, thereby inhibiting cell ferroptosis. Furthermore, we observed a significant reduction in lipid peroxidation products and ROS levels, we have also obtained the same results in vivo animal experiments. In conclusion, HSP played a protective role in CIRI by regulating intracellular iron ions levels, as well as GSH and GPX4 contents to inhibit neuronal ferroptosis after CIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.